Rubicon Research Limited announced key decisions from its Board of Directors meeting held on February 3, 2026. The board approved the appointment of Dr. Pradnya Saravade as Additional - Independent Woman Director for a term of three years, effective February 3, 2026, to February 2, 2029. Dr. Saravade brings extensive experience from her career in the Indian Police Service and regulatory bodies. The board also noted the resignation of Mr. Anand Agarwal as a Non-Executive Director, effective from the close of business on February 3, 2026. Additionally, M/s. BNP & Associates was approved as the Secretarial Auditor for FY 2025-26 and the subsequent four years until FY 2029-30. Furthermore, the company granted in-principle approval for the merger of its wholly-owned subsidiary, KIA Health Tech Private Limited, with Rubicon Research Limited. This merger is subject to board approval of the scheme of arrangement, regulatory approvals, and other administrative formalities. The net-worth of KIA Health Tech was ₹815.80 Lakhs and its total revenue was nil as of March 31, 2025. Rubicon Research's net-worth was ₹66,778.57 Lakhs and its total revenue was ₹1,09,352.40 Lakhs as of the same date. The rationale for the merger is to ensure operational synergies, and no cash consideration will be involved.
